Titomic is accumulating credible cold-spray adoption signals across aerospace repair, allied defense research, U.S. military sustainment and space evaluation. The challenge is no longer proving that the technology has applications. It is proving that those applications can become a scalable and financially efficient business.

During 2026, Titomic secured a repeat order from Lufthansa Technik, sold a multi-pressure cold-spray package to Royal NLR, signed a Space Act Agreement with NASA and established a multi-year research framework with a U.S. military organization.

These are stronger signals than isolated demonstrations because several involve repeat customers, paid equipment purchases and institutional pathways into defense and aerospace programs. However, Titomic remains an early-stage company with a cost base far larger than current revenue.

What changed?

• Lufthansa Technik ordered additional cold-spray capability worth more than A$1.2 million.
• The Lufthansa relationship has now been operating for approximately five years, making this a repeat-capacity order rather than a first trial.
• Royal NLR ordered low-, medium- and high-pressure cold-spray systems for €1.02 million.
• Titomic signed a Space Act Agreement with NASA for testing and evaluation of cold-spray components.
• Titomic USA signed a multi-year CRADA with a U.S. military research organization covering defense modernization, sustainment and materials development.
• An existing US$1.7 million defense-prime development contract is intended to validate manufacturing pathways for next-generation defense articles.
• The six months to December 2025 produced A$4.0 million of customer revenue, while the company remained deeply loss-making.
• Cash was A$35.8 million at December 2025 following the earlier A$50 million capital raise.

Why the Lufthansa order matters

Repeat orders are among the most useful adoption signals in additive manufacturing. Lufthansa Technik has used Titomic technology for aircraft-part repair for several years and is now expanding that capability at its Hamburg facility.

This suggests that cold spray has progressed beyond technical evaluation into an established maintenance workflow. Repair is especially attractive because it can restore high-value components without the thermal distortion associated with welding or melt-based additive processes.

The commercial value will depend on whether similar maintenance organizations adopt the same workflow and whether Titomic can generate recurring service, consumables and system-upgrade revenue from the installed base.

Royal NLR expands the allied aerospace pathway

Royal NLR’s order covers low-, medium- and high-pressure systems. That breadth allows the Dutch aerospace research center to evaluate repair, coatings and additive-manufacturing applications across a wider range of materials and component requirements.

The order improves Titomic’s position inside the European aerospace and defense ecosystem, but research-center adoption is not the same as production-scale demand. The key follow-through would be customer programs that move from application development into certified fleet or defense use.

NASA and the U.S. military create pathways—not guaranteed revenue

The NASA Space Act Agreement and military CRADA are strategically valuable because they create formal channels for testing, information exchange and joint development.

They should not be treated as firm production contracts. Their economic value depends on whether evaluations generate funded programs, qualification milestones and repeat manufacturing or sustainment work.

The strongest near-term evidence remains Titomic’s paid defense-prime development contract. If that work progresses from manufacturing development into low-rate initial production, it would mark a more meaningful transition toward recurring defense revenue.

Cold spray may be strongest in repair and sustainment

Titomic’s technology is often discussed as an additive-manufacturing platform, but its most commercially immediate applications may be coatings, corrosion protection and repair.

These markets already have urgent operational problems: aging fleets, long replacement lead times, material degradation and limited spare-part availability. Cold spray can deposit material without melting the substrate, making it useful where heat input would damage the component.

That focus could shorten commercialization timelines compared with entirely new structural components, which usually require longer qualification cycles.

The financial gap remains large

For the six months ended December 2025, Titomic reported A$4.0 million in customer revenue and A$5.3 million in total revenue, against a net loss of A$17.9 million.

The company is deliberately investing in U.S. production capacity, personnel and certification, but the numbers show how far revenue must scale before the model becomes self-sustaining.

The strengthened cash balance reduces immediate financing risk. It does not remove dilution risk if customer programs convert more slowly than expected.

What would prove the thesis?

• Lufthansa or other MRO customers place further repeat orders.
• Royal NLR programs progress into funded aerospace or defense deployments.
• The defense-prime development contract converts into low-rate production.
• NASA or military research agreements produce paid follow-on work.
• Repair and sustainment revenue becomes recurring rather than project-based.
• Gross margin improves as U.S. and European facilities gain utilization.
• Annual revenue grows materially faster than operating expenses.
• Operating cash burn declines toward management’s 2027 breakeven objective.

What would break the thesis?

• Research agreements fail to produce funded programs.
• Defense development work remains prototype-scale.
• Customer orders stay small and irregular.
• New facilities remain underutilized.
• Operating expenses continue to outpace revenue growth.
• Additional capital raises create substantial dilution.
• Qualification timelines extend beyond customer funding cycles.

Research conclusion

Titomic’s 2026 developments show broader and more credible market access. A repeat Lufthansa order, a paid Royal NLR system package and formal NASA and military pathways strengthen the commercial thesis.

But Titomic is not yet a scaled defense manufacturer. It remains a technology company investing ahead of revenue.

The decisive transition will occur when today’s evaluations and development contracts convert into repeat production, sustainment and aftermarket cash flows.

Research use only. This article is not investment advice.

Read the full Titomic investor profile →

Primary sources

• Lufthansa Technik repeat order
• Royal NLR system order
• NASA Space Act Agreement
• U.S. military CRADA
• Defense-prime development contract
• Titomic half-year financial report

Freemelt is accumulating the kind of customer signals that matter in advanced manufacturing: repeat machine orders, industrial deployments, defense projects and paid fusion-development work. The commercial story is strengthening—but the economics remain far from proven.

In 2025, Freemelt nearly tripled revenue and expanded its installed base to 40 systems. In 2026, it added orders from Jiuli, Intalus and TAE Technologies, while deepening its position in fusion, defense and critical materials.

The company is moving from a research-machine vendor toward an industrial E-PBF platform. The central question is whether those projects can convert into repeatable machine deliveries, recurring aftermarket revenue and a credible path to profitability.

What changed?

• 2025 net sales increased 172% to SEK 54.5 million.
• The installed base grew to 40 machines.
• Q1 2026 sales increased 116% year over year to SEK 6.3 million.
• Freemelt ended Q1 with seven active customer projects and a SEK 12.8 million order book.
• Intalus ordered two eMELT systems for approximately SEK 12 million, with options for at least two additional machines.
• Jiuli placed an additional eMELT order following the first Asian industrial-machine installation.
• TAE Technologies awarded Freemelt a tungsten feasibility-study order for fusion applications.
• Freemelt joined Proxima Fusion’s Alpha Alliance through a memorandum of understanding.
• Vinnova granted funding for projects with Saab Dynamics and Hitachi Energy.

Why the Intalus order matters

The Intalus order includes two eMELT machines, with delivery of the first system planned for late Q3 2026 and options for at least two more.

Intalus initially plans to use the systems for titanium-based medtech development, followed by potential work with refractory metals such as tungsten. The stated objective is a transition from application development toward serial additive manufacturing.

The order is important because it links the industrial eMELT platform to a customer roadmap rather than a one-off research purchase. The options for additional systems create a visible scaling path, although options should not be treated as firm revenue until exercised.

Jiuli provides the first repeat-order signal in Asia

Freemelt entered China through a strategic collaboration with Jiuli and delivered its first eMELT system during 2025. Jiuli’s additional machine order in June 2026 is therefore more meaningful than a first installation.

A repeat order suggests that the customer sees enough value in the platform to expand capacity. It also supports Freemelt’s claim that its open E-PBF architecture can be transferred into industrial materials and production-development workflows.

The next evidence threshold is utilization: whether the installed systems generate recurring projects, additional machines and aftermarket demand.

Fusion is strategically attractive—but commercially distant

Freemelt’s technology is particularly relevant to tungsten, one of the most difficult but strategically important materials in fusion energy. Tungsten’s heat resistance makes it a candidate for plasma-facing components, but its high melting point and brittleness make conventional processing and additive manufacturing difficult.

Freemelt is now working with UKAEA, TAE Technologies, Proxima Fusion and other fusion organizations. These engagements increase technical credibility and place the company inside emerging supply chains.

However, most fusion programs are still development-stage markets. Feasibility studies, memoranda and alliance memberships are not equivalent to serial-production revenue. The fusion thesis becomes financially meaningful only when customers move into qualified hardware programs and repeat procurement.

Defense and critical materials may convert faster

Freemelt has received follow-on work from a leading Swedish defense company and is participating in Vinnova-funded projects with Saab Dynamics and Hitachi Energy.

Defense applications may offer a nearer-term route to commercialization than fusion because customers already face material shortages, sovereign-supply requirements and demand for high-performance components. Yet the same caution applies: prototype and development work must progress into qualified production.

Sales growth has not yet solved the cost structure

Freemelt’s 2025 revenue growth was impressive, but the company remained deeply loss-making. In Q1 2026, sales were SEK 6.3 million while the operating loss was SEK 26.5 million.

This gap shows why order announcements alone are insufficient. Freemelt must scale revenue faster than engineering, commercial and corporate costs. Outsourced machine production through Scanfil may support a more capital-light model, but the company still needs enough volume and aftermarket revenue to absorb its fixed cost base.

The company’s long-term goal includes a meaningful contribution from service, maintenance and other recurring revenue. That mix shift would improve quality of earnings, but it depends on a much larger and actively used installed base.

What would prove the thesis?

• The Intalus systems are delivered on schedule and the options are exercised.
• Jiuli places additional repeat orders or expands industrial use.
• TAE, UKAEA or Proxima projects progress into larger hardware programs.
• Defense development projects convert into qualified production orders.
• eMELT becomes a growing share of machine deliveries.
• Aftermarket, service and maintenance revenue rise with the installed base.
• Order intake and backlog remain above prior-year levels.
• Operating losses narrow materially as revenue scales.

What would break the thesis?

• Fusion projects remain limited to studies and memoranda.
• Customer options do not convert into firm machine orders.
• Industrial systems are installed but underutilized.
• Revenue remains volatile and dependent on a small number of deliveries.
• Operating expenses continue to grow faster than sales.
• Additional capital raises create substantial dilution.
• Competing E-PBF or refractory-metal processes win key qualification programs.

Research conclusion

Freemelt has assembled one of the more differentiated strategic positions in public additive manufacturing. Its open E-PBF platform is relevant to tungsten, titanium, fusion, defense and high-value medtech applications.

The 2026 order flow is not merely promotional. It includes repeat industrial-machine orders, paid project work and multi-machine customer commitments. That is enough to strengthen the commercial thesis.

But Freemelt has not yet demonstrated industrial scale. The company must now convert technical relevance into higher system utilization, recurring revenue and a much narrower operating loss.

Research use only. This article is not investment advice.

Read the full Freemelt investor profile →

Primary sources

• Freemelt Q1 2026 interim report
• Freemelt 2025 annual report
• Two-machine Intalus order
• Freemelt 2026 press-release archive
• Freemelt announcements on Jiuli, TAE Technologies, Proxima Fusion, Saab Dynamics and Hitachi Energy

3D Systems entered 2026 with its clearest operating improvement in years. Dental, medtech and aerospace demand strengthened, gross margin improved and adjusted EBITDA turned positive. Then, less than a month later, the company raised $50 million through a new equity offering.

The contrast captures the investment case. The product and market thesis is improving. The balance-sheet and cash-generation thesis is not yet solved.

What changed?

• Q1 2026 revenue reached $95.5 million, up 1% year over year and 11% excluding divestitures.
• Healthcare Solutions revenue increased approximately 21% to $50.1 million.
• Dental, medtech and aerospace & defense each grew more than 20%.
• Gross margin improved to 35.9%, from 34.6%.
• Adjusted EBITDA improved to positive $2.1 million, from a large loss a year earlier.
• ROE Dental expanded its fleet of NextDent 300 systems across multiple sites.
• 3D Systems priced a $50 million upsized public offering at $3.05 per share.

Why dental matters more than a normal product cycle

Digital dentistry is one of the few additive-manufacturing markets with repeatable production volumes, recurring materials demand and a clear replacement path for conventional workflows.

3D Systems’ NextDent 300 jetted-denture solution targets monolithic, multi-material dentures. The significance is not only print speed. It is the possibility of combining automation, consistency and labor reduction in a market still dependent on skilled manual processes.

ROE Dental’s decision to add systems across multiple locations is a stronger commercial signal than a first installation. It suggests that the platform has moved beyond evaluation and is being deployed to expand real manufacturing capacity.

Healthcare is becoming the center of the company

Healthcare revenue now rivals the Industrial segment. That shift matters because dental and medtech applications can offer better utilization, recurring materials sales and more resilient demand than discretionary capital-equipment markets.

3D Systems also benefits from decades of regulatory, workflow and application knowledge. In healthcare, the moat is not simply the printer. It is the validated combination of hardware, materials, software and process expertise.

The Q1 recovery was real

Excluding divested software businesses, revenue grew 11%. Adjusted EBITDA improved by more than $25 million year over year and turned positive. Net loss also narrowed sharply.

This was not only a cost-cutting quarter. Growth in healthcare and aerospace & defense contributed to better mix and higher gross margin.

However, one positive quarter does not establish a durable earnings model. System demand remains cyclical, and product launches require working capital, inventory and commercial investment before revenue fully scales.

Why the equity raise changes the interpretation

In June, 3D Systems sold 16.4 million shares at $3.05 per share for approximately $50 million in gross proceeds. The underwriters also received an option for additional shares.

The capital strengthens liquidity and gives management more room to fund launches and operations. But it also dilutes existing shareholders and shows that the operating turnaround has not yet generated enough internal cash to remove financing risk.

The important question is therefore not whether the raise was necessary. It is whether this capital funds a self-sustaining growth cycle—or simply extends the runway until the next raise.

The strongest version of the thesis

The bull case is that 3D Systems has exited weaker software assets, reduced costs and concentrated resources on markets where it has genuine application depth. Dental, medtech and aerospace then drive higher-margin growth, while the installed base produces recurring materials and service revenue.

Under that scenario, the June offering becomes bridge capital used before a sustained profitability inflection.

The weaker version of the thesis

The bear case is that healthcare growth remains too narrow to offset cyclicality elsewhere, new-product adoption takes longer than expected and positive adjusted EBITDA fails to convert into positive free cash flow.

Under that scenario, dilution becomes a recurring feature rather than a one-time bridge.

What would prove the thesis?

• Dental and medtech sustain double-digit growth.
• ROE and other labs place follow-on NextDent 300 orders.
• Healthcare remains at least half of revenue with improving margins.
• Adjusted EBITDA stays positive over multiple quarters.
• Operating cash flow and free cash flow improve materially.
• Recurring materials and service revenue rise with installed-base utilization.
• The company avoids another major equity raise.
• Aerospace and defense product launches convert into repeat production orders.

What would break the thesis?

• Dental growth slows after the initial launch cycle.
• New systems are installed but underutilized.
• Gross margin fails to expand despite better mix.
• Positive adjusted EBITDA does not convert into cash.
• Industrial weakness overwhelms healthcare growth.
• Further financing creates substantial additional dilution.
• Product launches or regulatory approvals are delayed.

Research conclusion

3D Systems’ Q1 improvement was credible. Core revenue grew, healthcare became more important, dental adoption accelerated and adjusted EBITDA turned positive.

The $50 million equity raise does not invalidate that progress. It does, however, show that the turnaround is not yet self-funding.

For investors, the decisive milestone is now cash conversion. Product momentum has returned. Financial independence has not.

Research use only. This article is not investment advice.

Read the full 3D Systems investor profile →

Primary sources

• 3D Systems Q1 2026 results
• ROE Dental multi-site deployment
• $50 million public offering
• SEC filing for the June 2026 offering

AML3D’s U.S. defense story is beginning to look like deployment rather than experimentation. The company now has operating systems inside Newport News Shipbuilding, four more on order and a paid contract to manufacture submarine components for in-service trials.

That does not yet prove a scalable business. But it is stronger evidence than a typical additive-manufacturing pilot because customers are buying multiple systems, commissioning them inside strategic shipyards and assigning real supply-chain problems to the technology.

What changed?

• Newport News Shipbuilding ordered four ARCEMY X systems for approximately A$9.9 million.
• The order will take NNS to six custom ARCEMY X systems.
• The first two NNS systems, from an earlier A$4.5 million order, were commissioned in June 2026.
• AML3D received an approximately A$2.61 million order to manufacture five U.S. Navy submarine components.
• The components will be used in in-service trials and address parts no longer supported by the original manufacturer.
• The first portable ARCEMY system became operational at the U.S. Navy Additive Manufacturing Center of Excellence.
• AML3D is investing to double capacity at its Stow, Ohio technology and manufacturing center.

Why six systems at HII matter

A single machine can be a technology evaluation. A fleet of six systems inside the largest U.S. military shipbuilder points to a more durable commitment.

Newport News Shipbuilding builds nuclear-powered aircraft carriers and submarines. Its production challenges include long lead times, constrained suppliers and large metal components that are difficult to source conventionally. Large-format wire-arc additive manufacturing is relevant because it can create near-net-shape parts faster and with less material waste than some traditional routes.

The first two systems are now commissioned, while four additional systems are scheduled for delivery in early 2027. That progression—from initial order, to commissioning, to fleet expansion—is one of the strongest commercial signals in AML3D’s history.

The submarine-parts contract is more important than its size

The A$2.61 million contract covers five large, non-safety-critical replacement components for in-service trials on U.S. Navy submarines. The components are no longer available from the original manufacturer, creating a clear sustainment problem.

AML3D will print the parts in nickel-aluminum-bronze, an alloy it has already qualified to U.S. Navy standards. This follows successful hydrostatic testing of earlier components.

The significance is not the revenue alone. It is the transition from printing prototypes to manufacturing parts intended for operational evaluation. If the components perform successfully, the addressable opportunity could expand to additional obsolete or supply-constrained naval parts.

A distributed production network may be forming

AML3D’s installed base is spreading across several parts of the U.S. Maritime Industrial Base. Systems are operating or planned at Newport News Shipbuilding, the Navy’s Additive Manufacturing Center of Excellence, FasTech and other defense-related suppliers.

This matters because the strongest business model may not be centralized contract manufacturing. It may be a distributed network of customer-owned ARCEMY systems supported by AML3D software, qualification, service and process knowledge.

Such a network could create recurring service and support revenue while embedding AML3D’s process into customer production systems. It could also reduce shipping and lead-time constraints by moving manufacturing closer to point of need.

The U.S. Navy demand forecast is not guaranteed revenue

AML3D has cited a U.S. Navy letter of intent identifying its technology as relevant to a broader plan for additive-manufacturing installations and component output. Those forecasts are strategically encouraging, but they should not be treated as firm purchase orders.

The investable evidence is the signed order book: systems sold, systems commissioned and paid parts contracts. Future fleet and component forecasts remain upside scenarios until they become funded awards.

The financial challenge

AML3D is still a relatively small company pursuing an aggressive international scale-up. Expanding the Ohio facility, manufacturing custom systems and supporting defense qualification require working capital, technical staff and execution discipline.

Large orders can create uneven revenue recognition and cash-flow timing. Investors should distinguish headline order value from delivery milestones, final acceptance and gross profit.

The company’s next phase must demonstrate that growing U.S. defense demand can produce repeatable margins rather than only larger project volumes.

What would prove the thesis?

• The four additional HII systems are delivered on schedule in early 2027.
• The first two HII systems reach meaningful production utilization.
• The five submarine components complete in-service trials successfully.
• Additional parts orders follow from the same qualification pathway.
• More U.S. Navy suppliers purchase ARCEMY systems.
• Service, maintenance and software revenue grow with the installed base.
• Ohio capacity expansion is completed without major cost overruns.
• Gross margin and operating cash flow improve as U.S. revenue scales.

What would break the thesis?

• HII deliveries are delayed or systems remain underutilized.
• Submarine components fail testing or do not generate follow-on orders.
• Defense forecasts remain non-binding and convert slowly.
• Expansion costs consume cash faster than customer payments arrive.
• Custom engineering requirements limit standardization and margins.
• Alternative manufacturing technologies win the same sustainment work.
• Revenue remains concentrated in a small number of U.S. defense customers.

Research conclusion

AML3D has not yet proven a mature, high-margin production platform. But its U.S. naval position is no longer supported only by demonstrations or memoranda.

Systems are being commissioned at the largest U.S. military shipbuilder. That customer has already ordered four more. The U.S. Navy is also paying AML3D to manufacture replacement components for operational trials.

This is credible evidence of adoption. The next stage is to prove utilization, repeat orders and financial scalability.

Research use only. This article is not investment advice.

Read the full AML3D investor profile →

Primary sources

• AML3D A$9.9 million HII-NNS order
• First ARCEMY systems operational at Newport News Shipbuilding
• AML3D U.S. Navy submarine-parts order
• Portable ARCEMY system at the U.S. Navy AM Center of Excellence
• U.S. Navy letter of intent and demand forecast
• AML3D ASX announcements

Materialise did not grow in the first quarter of 2026. Yet the company may have delivered something more important: better margins, positive free cash flow, stronger net cash and a more focused portfolio.

The quarter highlights a different kind of additive-manufacturing thesis. Materialise is not trying to win through aggressive hardware volume or acquisition-led scale. It is attempting to improve the quality of a diversified business built around medical applications, software and manufacturing services.

What changed?

• Q1 2026 revenue was stable at €66.3 million.
• Gross margin increased to 57.2%, from 55.3% a year earlier.
• Adjusted EBIT rose to €2.47 million, from €0.65 million.
• Adjusted EBITDA increased to €8.05 million, from €6.15 million.
• Net profit reached €1.82 million, versus a €0.54 million loss.
• Operating cash flow was €6.91 million and free cash flow was positive.
• Net cash increased to €72.8 million.
• Medical revenue grew 6.7%, while Manufacturing revenue declined 8.1%.
• Materialise transferred its eyewear business to management after selling Rapidfit.

Flat revenue can still hide a better quarter

Total revenue was almost unchanged year over year, but the income statement improved materially. Gross profit rose despite flat sales, adjusted EBIT nearly quadrupled and all three operating segments improved adjusted EBITDA.

This suggests that the company is getting more disciplined about pricing, mix and operating cost. Research, sales and administrative expenses remained broadly stable in aggregate, allowing gross-margin gains to flow through to profit.

The improvement is more credible because it also appeared in cash flow. Materialise generated positive operating and free cash flow while increasing net cash and buying back shares.

Medical remains the economic engine

Materialise Medical generated €33.2 million of revenue, up 6.7%, and €9.2 million of adjusted EBITDA. The segment represented roughly half of group revenue but substantially more than half of segment EBITDA.

This matters because medical additive manufacturing is built around patient-specific workflows, regulated software, clinical relationships and repeatable procedure volumes. Those characteristics can create stronger switching costs and more resilient economics than general-purpose printing services.

The risk is that Medical’s adjusted EBITDA margin slipped to 27.8% from 29.1%. Growth remains healthy, but investors should watch whether future investment or pricing pressure limits margin expansion.

Software is showing operating leverage

Software revenue declined 1.4%, yet segment adjusted EBITDA rose 87% and margin improved to 11.6% from 6.1%.

That is encouraging because software should ultimately be one of Materialise’s most scalable assets. The company’s long-term value depends not only on selling licenses, but on embedding its workflow, build-preparation and quality tools inside industrial production systems.

The next step is top-line acceleration. Margin improvement without revenue growth can support earnings for a period, but durable software value requires rising adoption and recurring revenue.

Manufacturing is still the weak point

Manufacturing revenue fell 8.1% to €23.5 million. Segment adjusted EBITDA improved from a loss to a small positive result, but the 1.2% margin remains thin.

The segment is exposed to customer project timing, industrial cyclicality and price competition. It also carries a more capital- and labor-intensive cost structure than software.

The encouraging signal is that management restored positive segment EBITDA despite lower revenue. The stronger signal would be revenue stabilization accompanied by a sustained mid-single-digit or better margin.

Exiting eyewear and Rapidfit sharpens the portfolio

Materialise sold Rapidfit at the end of March and then agreed to transfer its eyewear activities to the eyewear management team. Materialise will retain a minority stake in the new eyewear company, while the financial terms were not disclosed.

These actions indicate that management is willing to remove businesses that consume capital or attention without strengthening the core platform. The company expects an impairment charge related to eyewear in Q2, so the exit is not costless.

Strategically, however, the direction is clear: concentrate resources on Medical, Software and selected Manufacturing capabilities where Materialise has stronger differentiation.

The balance sheet is becoming an advantage

Materialise ended Q1 with €133.0 million of cash, €60.1 million of gross debt and €72.8 million of net cash. The company also continued its share-buyback program.

That financial position distinguishes Materialise from many pure-play AM peers that rely on recurring equity issuance. It gives the company flexibility to invest in software, medical growth and selective strategic opportunities without immediate financing pressure.

Still, buybacks create value only if the business compounds earnings and cash flow. They should not substitute for organic growth.

What would prove the thesis?

• Medical sustains mid- to high-single-digit growth with stable margins.
• Software returns to growth while maintaining double-digit adjusted EBITDA margins.
• Manufacturing revenue stabilizes and margin rises meaningfully above breakeven.
• Adjusted EBIT reaches the €10 million to €12 million 2026 guidance range.
• Free cash flow remains positive over multiple quarters.
• Portfolio exits reduce complexity without weakening customer relationships.
• Net cash continues to rise after investment and buybacks.
• Management demonstrates that capital allocation improves per-share value.

What would break the thesis?

• Medical growth slows materially or margins continue to compress.
• Software remains stagnant despite cost improvements.
• Manufacturing stays structurally low margin.
• Eyewear and other exits generate larger-than-expected impairment or restructuring costs.
• Free cash flow improvement proves temporary.
• Share buybacks consume cash without improving earnings power.
• Full-year revenue or adjusted EBIT guidance is reduced.

Research conclusion

Materialise’s first-quarter results did not show a growth breakout. They showed something rarer in the public additive-manufacturing universe: operating discipline, positive free cash flow and a strong net-cash position.

The company is also narrowing its portfolio around areas where it has deeper technical and commercial advantages.

The thesis is therefore improving in quality rather than speed. Materialise now needs to prove that better margins and portfolio focus can support renewed top-line growth.

Research use only. This article is not investment advice.

Read the full Materialise investor profile →

Primary sources

• Materialise Q1 2026 results and eyewear transfer
• Materialise May 2026 Form 6-K
• Materialise share-buyback update
• Materialise July 2026 share-buyback update

Stratasys is buying Markforged to deepen its exposure to aerospace, defense and industrial production. The strategic logic is stronger than a simple portfolio expansion—but the deal will only matter if Stratasys converts a broader technology stack into better economics.

On May 27, 2026, Stratasys agreed to acquire Markforged from Nano Dimension in a $42.5 million all-cash transaction. The purchase adds continuous-carbon-fiber FFF systems, secure workflow software and an industrial customer base to Stratasys’ existing polymer additive-manufacturing platform.

The transaction could create one of the industry’s broadest production-oriented polymer AM offerings. But breadth alone is not a moat. The real test is whether Stratasys can produce cross-sales, recurring consumables, stronger channel productivity and positive incremental EBITDA.

What changed?

• Stratasys agreed to acquire Markforged for $42.5 million in cash.
• The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.
• Markforged generated approximately $70 million of revenue in 2025, including a metal binder-jetting line that Nano Dimension will retain.
• Stratasys expects meaningful cost synergies and positive adjusted EBITDA contribution within the first year after closing.
• Q1 2026 Stratasys revenue was $132.7 million, compared with $136.0 million a year earlier.
• Adjusted EBITDA fell to $2.0 million, from $8.2 million.
• Stratasys ended Q1 with $237.8 million in cash, equivalents and short-term deposits and no debt.

Why Markforged fits Stratasys

Stratasys already has scale in polymer printing, an extensive installed base, application expertise and recurring revenue from consumables and service. Markforged adds a differentiated continuous-fiber platform, secure software and a stronger presence in rugged factory-floor applications.

The combination is especially relevant in aerospace and defense, where customers need lightweight tooling, fixtures, replacement components and low-volume production parts that can be manufactured close to the point of use. Markforged’s Digital Forge platform is designed around controlled workflows, simulation and repeatability—capabilities that matter more than raw printing speed in regulated environments.

Stratasys also gains a broader channel and more opportunities to sell materials, software, support and additional systems into existing customer accounts.

This is not a metal-AM acquisition

Nano Dimension will retain Markforged’s metal binder-jetting product line. Investors should therefore avoid describing the deal as a full acquisition of Markforged’s historical metal portfolio.

The asset Stratasys is acquiring is primarily the end-to-end FFF platform, including continuous-fiber capabilities, software, materials and customer relationships. The strategic rationale is production-grade polymer and composite manufacturing—not ownership of a broad metal-printing platform.

The purchase price looks manageable

At $42.5 million, the transaction represents a relatively modest use of Stratasys’ liquidity. The company held $237.8 million in cash, equivalents and short-term deposits at the end of Q1 and reported no debt.

That financial capacity reduces balance-sheet risk, but a low purchase price does not guarantee a high return. Markforged has changed ownership after a period of public-market losses and restructuring. The burden is now on Stratasys to demonstrate that the acquired revenue can be stabilized and made profitable.

Why the deal matters now

Stratasys’ Q1 results showed a stable but pressured business. Revenue declined modestly, gross margins compressed and adjusted EBITDA fell sharply. At the same time, Stratasys Direct delivered strong organic growth led by drone customers, and management highlighted a building pipeline in high-requirement defense applications.

Markforged gives Stratasys a way to increase exposure to those applications without building every capability internally. If the combined platform wins production programs, the deal could improve mix and reinforce recurring revenue. If it merely adds overlapping channel and operating costs, it could distract from the core margin-recovery plan.

The integration challenge

Stratasys must integrate products, sales teams, software, service networks and materials strategies without confusing customers or weakening channel incentives. It must also decide which workflows remain distinct and where consolidation creates value.

The strongest outcome would not be a single oversized product catalog. It would be a coherent application ladder: customers start with tooling or fixtures, scale into production cells, and generate recurring demand for materials, software and support.

What would prove the thesis?

• The transaction closes on schedule and near the announced purchase price.
• Markforged contributes positive adjusted EBITDA within the first year.
• Stratasys quantifies and delivers cost synergies.
• Cross-selling produces measurable system, material or service revenue.
• Recurring revenue grows as a percentage of the combined business.
• New aerospace and defense programs adopt the combined platform.
• Operating margin improves despite integration costs.
• Stratasys maintains balance-sheet strength and avoids a large restructuring charge.

What would break the thesis?

• The transaction is delayed or blocked.
• Markforged revenue continues to decline after closing.
• Expected synergies fail to offset integration costs.
• Channel overlap creates customer or distributor disruption.
• The combined portfolio remains focused on prototyping rather than production.
• Adjusted EBITDA contribution is delayed beyond the first year.
• Stratasys’ core margins continue to deteriorate.

Research conclusion

The Markforged acquisition gives Stratasys a stronger strategic position in composite tooling, factory-floor manufacturing and high-requirement applications. It also expands the company’s customer network and software-enabled workflow capabilities at a manageable purchase price.

But the transaction is not yet evidence that Stratasys has solved production additive manufacturing. That requires profitable growth, repeatable application wins and rising recurring revenue.

The deal strengthens the platform. Execution after closing will determine whether it strengthens the business.

Research use only. This article is not investment advice.

Read the full Stratasys investor profile →

Primary sources

• Stratasys acquisition announcement
• Stratasys Q1 2026 results
• Stratasys Form 6-K on the transaction
• Nano Dimension Form 8-K on the sale

Velo3D is starting to look less like a distressed printer vendor and more like a defense-oriented production platform. The evidence is improving—but the company has not yet escaped its capital intensity.

In the first half of 2026, Velo3D reported faster revenue growth, positive gross margin, a five-year Defense Logistics Agency contract, a major production-campus expansion and another Sapphire XC order from Mears Machine. Taken together, these developments suggest that demand is moving beyond demonstrations and into repeatable production capacity.

The central question is no longer whether Velo3D can print difficult aerospace and defense parts. It is whether the company can scale that capability without repeatedly diluting shareholders.

What changed?

• Q1 2026 revenue reached $13.8 million, up 48% year over year.
• Gross margin improved to 17.2%, from 7.5% a year earlier.
• Adjusted EBITDA loss narrowed to $3.6 million, from $6.9 million.
• Bookings were $12 million and backlog ended the quarter at $30 million.
• Velo3D won a $9.8 million, five-year DLA IDIQ contract supporting the Joint Additive Manufacturing Acceptability pilot-parts program.
• The company announced a 288,747-square-foot Livermore production campus designed to support more than 100 metal printers.
• Mears Machine ordered a fifth Sapphire XC, with options for two more systems.

Why the Mears order matters more than a normal printer sale

A first machine can be experimentation. A fifth machine is different. It implies that a customer has already invested in operators, qualification, workflow integration and downstream machining—and still sees enough demand to expand.

Mears is using the platform across aviation, defense, energy and space, including advanced nickel alloys and aluminum. The strategic value is not just machine revenue for Velo3D. A growing multi-machine customer base can validate machine-to-machine consistency, process repeatability and distributed production—all essential if additive manufacturing is to move from isolated qualification programs into scalable supply chains.

The DLA contract is a pathway, not guaranteed revenue

The $9.8 million award is an indefinite-delivery, indefinite-quantity contract. That distinction matters. It creates a procurement vehicle through which qualified parts can be ordered, but the headline ceiling should not be treated as immediately secured revenue.

Even so, the contract is strategically important. Defense sustainment is one of the strongest use cases for metal additive manufacturing because many components suffer from long lead times, obsolete tooling or a shrinking domestic supplier base. Velo3D’s Rapid Production Solution is aimed directly at this bottleneck.

The Livermore expansion raises both upside and risk

Velo3D says the Livermore campus will triple production capacity and can support more than 100 metal printers. If demand is real, this could shift the company toward a more diversified model combining system sales with recurring parts production.

But capacity announcements are not the same as utilized capacity. The facility must be equipped, commissioned, staffed and filled with qualified work. Management expects 2026 capital expenditure of $40 million to $50 million, primarily for Rapid Production Solution expansion—and explicitly notes that this spending depends on sufficient financing.

This makes utilization the key variable. A large facility with low loading would worsen cash burn. A highly utilized facility serving defense and aerospace programs could improve gross margin, recurring revenue and customer stickiness.

The balance-sheet problem has improved, not disappeared

Velo3D ended March with $16.6 million of cash, down from $39.0 million at year-end. In April, it sold 3,571,428 shares at $14 per share, raising approximately $50 million before fees. It also completed debt-to-equity conversions and reduced outstanding debt to roughly $9 million.

The financing gives the company room to invest, but it also shows why the investment case remains fragile. The operational recovery is being funded partly through dilution. For shareholders, the relevant question is whether the new equity creates a self-sustaining production business—or merely postpones the next financing requirement.

What would prove the thesis?

• Revenue reaching the company’s $60 million to $70 million 2026 range.
• Gross margin exceeding 30% in the second half, as guided.
• Positive EBITDA in the second half of 2026.
• Backlog growth and visible conversion into revenue.
• More repeat customers ordering third, fourth or fifth systems.
• DLA task orders converting the IDIQ vehicle into actual production revenue.
• RPS parts revenue becoming a meaningful recurring share of the mix.
• Livermore ramping without major cost overruns or another near-term equity raise.

What would break the thesis?

• The new campus opens slowly or operates below planned utilization.
• Defense awards remain pilot-scale and fail to convert into repeat orders.
• Gross margin stalls below management’s target.
• System sales remain lumpy while parts production fails to scale.
• Cash burn forces another substantial financing round.
• Customers delay capital spending or choose competing LPBF platforms.

Research conclusion

Velo3D’s 2026 developments are stronger than a typical sequence of promotional partnerships. Revenue is growing, margins are improving, a repeat customer is expanding its fleet, the company has secured a defense procurement pathway and management is building capacity around a parts-production model.

That is enough to strengthen the operating thesis. It is not enough to declare the turnaround complete.

The decisive transition will occur only when qualified demand fills the new capacity and generates sustainable cash flow. Until then, Velo3D remains a high-upside production-AM story financed by a balance sheet that still requires close attention.

Research use only. This article is not investment advice.

Read the full Velo3D investor profile →

Primary sources

• Velo3D Q1 2026 financial results
• Velo3D DLA contract announcement
• Velo3D Livermore production-campus announcement
• Mears Machine fifth Sapphire XC order
• SEC filing for the April 2026 registered direct offering

Nano Dimension’s original additive-manufacturing roll-up thesis is being dismantled. The company is selling product lines, divesting Markforged and proposing to redeploy its cash and Nasdaq listing into an AI-powered preventive-health business.

For investors, this is no longer primarily an additive-manufacturing operating story. It is becoming a transaction, capital-allocation and residual-value story.

What changed?

• Nano sold its AME and Fabrica product lines for up to $12.5 million, including $2.0 million upfront and performance-based deferred payments.
• The company agreed to sell Markforged to Stratasys in a $42.5 million all-cash transaction, while retaining the Markforged metal binder-jetting product line.
• The two announced monetization actions are expected to reduce annualized cash burn by approximately $25 million.
• Q1 2026 revenue was $29.7 million, but adjusted EBITDA loss widened to $12.5 million and net loss reached $69.7 million, including a $40.4 million impairment.
• Liquidity was $441.6 million at March 31, 2026.
• Full-year guidance was suspended as the strategic-alternatives process accelerated.
• Nano signed a non-binding term sheet with Infinite Epigenetics for a proposed business combination valued at $890 million for Infinite.

The AM roll-up is unwinding

Nano Dimension spent years assembling a broad digital-manufacturing portfolio through acquisitions. The intended logic was scale, cross-selling and exposure to electronics, polymers, composites and metal additive manufacturing.

Management’s current actions imply that the portfolio did not generate sufficient strategic or financial returns. The company’s chief executive has stated that acquisitions made under prior leadership were too costly for the benefits obtained. The response is now straightforward: reduce operating expense, sell product lines and seek a different use for the balance sheet and public-company platform.

This matters because investors should not interpret reported revenue growth as evidence that the original strategy succeeded. Q1 revenue more than doubled largely because acquired businesses were included in the comparison. At the same time, adjusted EBITDA losses widened and the company recorded a major impairment.

Selling Markforged changes the identity of the company

Markforged was one of Nano Dimension’s most recognizable industrial AM assets. Its continuous-fiber composite systems, metal platforms, software and installed base offered a credible route into production applications.

The proposed $42.5 million sale to Stratasys is therefore more than a cost-cutting measure. It transfers much of Nano’s most visible operating exposure to another AM platform. Nano will retain the metal binder-jetting product line, but the broader investment identity is clearly moving away from being a diversified additive-manufacturing consolidator.

The Infinite Epigenetics proposal is effectively a strategic pivot

On June 15, Nano announced a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive-health and diagnostics company built around epigenetic data, a CLIA-certified laboratory and consumer-health operations.

If completed, the combined company is expected to operate under the Infinite Epigenetics name and trade under the proposed ticker IEAI. Existing Nano shareholders would retain a meaningful minority interest based on a stated value for Nano that reflects a 20% premium to estimated net cash at closing. They would also receive a contingent value right tied to potential proceeds from certain legacy Nano assets.

That structure makes the future investment case fundamentally different. Shareholders would own a minority stake in a healthcare-AI platform plus a claim on uncertain legacy-asset proceeds. The value of Nano’s remaining AM operations would become secondary to transaction economics.

Why the headline premium requires caution

The stated 20% premium is based on estimated net cash at closing—not necessarily on the current market price or a fixed cash payment to shareholders. The final exchange ratio, ownership split, cash balance, transaction expenses and treatment of remaining liabilities will determine the actual economic outcome.

The term sheet is also non-binding. There is no assurance that the parties will sign a definitive agreement or complete the combination. Shareholder, regulatory and other approvals would still be required.

What remains of the additive-manufacturing exposure?

Nano continues to operate remaining product lines and will retain Markforged’s metal binder-jetting business under the announced Stratasys transaction. But the company’s strategic priorities are now monetization and redeployment rather than building an integrated AM platform.

For Addithive’s company universe, this means Nano Dimension should increasingly be treated as a special situation rather than a clean additive-manufacturing pure play.

What would prove the new thesis?

• A definitive merger agreement with transparent ownership and valuation terms.
• Evidence that estimated net cash at closing remains close to current expectations.
• Completion of the Markforged sale at the announced value.
• Further monetization of legacy assets without excessive transaction costs.
• Clear financial disclosure for Infinite Epigenetics, including revenue growth, gross margin, cash burn and path to profitability.
• A credible valuation bridge supporting the $890 million transaction value.
• Meaningful and realizable value from the contingent value right.

What would break the thesis?

• The Infinite transaction fails or is materially delayed.
• The final exchange ratio gives Nano shareholders less ownership than expected.
• Cash declines significantly before closing.
• Legacy assets are sold at weak valuations or produce little CVR value.
• Infinite’s operating metrics do not justify the proposed valuation.
• The company incurs prolonged corporate costs while strategic actions remain incomplete.
• Shareholder disputes or governance conflict obstruct execution.

Research conclusion

Nano Dimension is not simply restructuring an additive-manufacturing company. It is attempting to transform the public entity into a different business.

The sale of AME, Fabrica and Markforged may reduce cash burn and simplify the organization. But these actions also confirm that the original AM roll-up did not produce the expected operating leverage.

From here, shareholder outcomes depend on capital preservation, transaction discipline and the quality of Infinite Epigenetics. Investors seeking direct additive-manufacturing exposure should no longer treat Nano Dimension as a straightforward pure-play AM company.

Research use only. This article is not investment advice.

Read the full Nano Dimension investor profile →

Primary sources

• Nano Dimension Q1 2026 results
• Sale of AME and Fabrica product lines
• Sale of Markforged to Stratasys
• CEO letter on strategic restructuring
• Infinite Epigenetics proposed business combination
• SEC filing on strategic alternatives